Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance

ARTELO BIOSCIENCES, INC.

Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.
Net proceeds of $10.03M to be used for working capital, corporate purposes, and repayment of bridge debt.
Common warrants exercisable at $3.20 for 5.5 years; potential additional proceeds of $20.4M if fully cash-exercised.
Proceeds push stockholders' equity above $2.5M threshold; company awaiting Nasdaq confirmation of compliance.
H.C. Wainwright acted as placement agent, receiving 8% cash fee plus warrants for 255,073 shares at $4.3125.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $10,996,902.70
Effective: 2026-03-27

Exact text from the filing

On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.